Natixis Bio N Tech Se Transaction History

Natixis

  • $17.6 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$80.36 - $102.87 $53,760 - $68,820
-669 Reduced 84.36%
124 $9,000
Q1 2024

May 13, 2024
SELL
$88.96 - $112.35 $37,541 - $47,411
-422 Reduced 34.73%
793 $73,000
Q4 2023

Feb 13, 2024
BUY
$90.91 - $112.75 $18,363 - $22,775
202 Added 19.94%
1,215 $128,000
Q3 2023

Nov 14, 2023
SELL
$98.5 - $125.08 $576,225 - $731,718
-5,850 Reduced 85.24%
1,013 $110,000
Q2 2023

Aug 11, 2023
SELL
$102.58 - $129.66 $62,778 - $79,351
-612 Reduced 8.19%
6,863 $740,000
Q1 2023

May 12, 2023
BUY
$122.57 - $153.67 $297,599 - $373,110
2,428 Added 48.11%
7,475 $931,000
Q4 2022

Feb 24, 2023
BUY
$118.43 - $186.05 $597,716 - $938,994
5,047 New
5,047 $758,000
Q2 2022

Aug 12, 2022
SELL
$123.25 - $186.24 $1.56 Million - $2.36 Million
-12,657 Closed
0 $0
Q1 2022

May 13, 2022
SELL
$126.25 - $231.85 $367,261 - $674,451
-2,909 Reduced 18.69%
12,657 $2.16 Million
Q4 2021

Feb 14, 2022
SELL
$216.64 - $362.52 $1.33 Million - $2.22 Million
-6,134 Reduced 28.27%
15,566 $4.01 Million
Q3 2021

Nov 12, 2021
BUY
$205.93 - $447.23 $3.64 Million - $7.9 Million
17,669 Added 438.33%
21,700 $5.92 Million
Q2 2021

Aug 13, 2021
SELL
$113.32 - $241.49 $56,093 - $119,537
-495 Reduced 10.94%
4,031 $902,000
Q1 2021

May 14, 2021
SELL
$85.73 - $119.5 $15.3 Million - $21.3 Million
-178,460 Reduced 97.53%
4,526 $495,000
Q4 2020

Feb 12, 2021
SELL
$72.71 - $129.54 $8.94 Million - $15.9 Million
-123,014 Reduced 40.2%
182,986 $14.9 Million
Q3 2020

Nov 12, 2020
BUY
$57.81 - $104.17 $17.7 Million - $31.9 Million
306,000 New
306,000 $21.2 Million

Others Institutions Holding BNTX

# of Institutions
358
Shares Held
38.4M
Call Options Held
2.45M
Put Options Held
2.29M
View Full List

About BioNTech SE

BNTX Quotes by TradingView
  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $24.2B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email